(Total Views: 368)
Posted On: 11/07/2017 12:46:34 PM
Post# of 1460
Copy from another poster I follower on IHUB,
Fletch
dadofmarcmax Tuesday, 11/07/17 12:39:08 PM
Re: kevindenver post# 129379
Post # of 129397
Speaking of ibuprofen.....you do know that it is a nonsteroidal anti-inflammatory drug (NSAID).
Did you also know that people with a higher exposure to ibuprofen in a lifetime have a lesser risk of developing Alzheimer's disease?
While certainly not proof that Alzheimer's is the result of an inflammatory process, this fact certainly points that this theory - that AD is related to chronic neuroinflammation - is likely to be reality.
Amyloid-beta plaques - are just biproducts of chronic neuroinflammation and getting rid of the plaques will do nothing to stop the upstream process that is causing neurodegeneration. This upstream process is neuroinflammation.
I consider Anavex 2-73, in essence, as an anti-inflammatory agent that works against chronic neuroinflammation - a complicated pathophysiological process that can lead to varied neurological pathologies in the old and young. Hence why Anavex 2-73 has so many applications potentially to seemingly different neurological conditions.
We essentially have one of the newest and potentially the most versatile anti-inflammatory agent that is non-steroidal in nature but not of the same MOA as other NSAIDs. This is a whole new class of anti-inflammatory agents, in my opinion only.
As a physician who often errs of the controversial side of the science spectrum, I am a believe that chronic neuroinflammation leads to many neurological disorders and by tackling this using unique agents like A-273 or other agents that act on the endocannabinoid system - we have tools to start tackling chronic inflammatory processes.
This is getting exciting!
BTW, I will be at AES (American Epilepsy Society) conference this year. Does anyone know if Anavex plans on attending?
Fletch
dadofmarcmax Tuesday, 11/07/17 12:39:08 PM
Re: kevindenver post# 129379
Post # of 129397
Speaking of ibuprofen.....you do know that it is a nonsteroidal anti-inflammatory drug (NSAID).
Did you also know that people with a higher exposure to ibuprofen in a lifetime have a lesser risk of developing Alzheimer's disease?
While certainly not proof that Alzheimer's is the result of an inflammatory process, this fact certainly points that this theory - that AD is related to chronic neuroinflammation - is likely to be reality.
Amyloid-beta plaques - are just biproducts of chronic neuroinflammation and getting rid of the plaques will do nothing to stop the upstream process that is causing neurodegeneration. This upstream process is neuroinflammation.
I consider Anavex 2-73, in essence, as an anti-inflammatory agent that works against chronic neuroinflammation - a complicated pathophysiological process that can lead to varied neurological pathologies in the old and young. Hence why Anavex 2-73 has so many applications potentially to seemingly different neurological conditions.
We essentially have one of the newest and potentially the most versatile anti-inflammatory agent that is non-steroidal in nature but not of the same MOA as other NSAIDs. This is a whole new class of anti-inflammatory agents, in my opinion only.
As a physician who often errs of the controversial side of the science spectrum, I am a believe that chronic neuroinflammation leads to many neurological disorders and by tackling this using unique agents like A-273 or other agents that act on the endocannabinoid system - we have tools to start tackling chronic inflammatory processes.
This is getting exciting!
BTW, I will be at AES (American Epilepsy Society) conference this year. Does anyone know if Anavex plans on attending?
(0)
(0)Scroll down for more posts ▼
